UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 34

Sortiert nach

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226

2022

Volltextzugriff (PDF)

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

BMC cancer, 2023-08, Vol.23 (1), p.1-792, Article 792

2023

Volltextzugriff (PDF)

Impact of Required Versus Self-Directed Use of Virtual Patient Cases on Clerkship Performance: A Mixed-Methods Study

Academic medicine, 2018-05, Vol.93 (5), p.742-749

2018

Volltextzugriff (PDF)

A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

Pediatric blood & cancer, 2014-04, Vol.61 (4), p.636-642

2014

Volltextzugriff (PDF)

A Stroke Mimic: Methotrexate-induced Neurotoxicity in the Emergency Department

The Journal of emergency medicine, 2017-04, Vol.52 (4), p.559-561

2017

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355

Cancer medicine (Malden, MA), 2023-05, Vol.12 (9), p.10280-10293

2023

Volltextzugriff (PDF)

Outcomes and patterns of care in a nationwide cohort of pediatric medulloblastoma: Factors affecting proton therapy utilization

Advances in radiation oncology, 2017-10, Vol.2 (4), p.588-596

2017

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer

Future oncology (London, England), 2024-04, p.1-14

2024

Volltextzugriff (PDF)

Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1

European journal of cancer (1990), 2022-12, Vol.177, p.45-52

2022

Volltextzugriff (PDF)

Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study

JNCI : Journal of the National Cancer Institute, 2024-06

2024

Volltextzugriff (PDF)

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Future oncology (London, England), 2024-02, Vol.20 (6), p.335-348

2024

Volltextzugriff (PDF)

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.503-503

2022

Volltextzugriff (PDF)

PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer

Annals of oncology, 2022-07, Vol.33, p.S465

2022

Volltextzugriff (PDF)

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS1-02-GS1-02

2022

Volltextzugriff (PDF)

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

Advances in therapy, 2023-03, Vol.40 (3), p.1153-1170

2023

Volltextzugriff (PDF)

Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer

Immunotherapy, 2022-09, Vol.14 (13), p.1027-1041

2022

Volltextzugriff (PDF)

Underutilization of proton therapy in the treatment of pediatric central nervous system tumors: an analysis of the National Cancer Database

Acta oncologica, 2017-08, Vol.56 (8), p.1122-1125

2017

Volltextzugriff (PDF)

Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (5_Supplement), p.PD3-01-PD3-01

2023

Volltextzugriff (PDF)

Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study

JNCI : Journal of the National Cancer Institute, 2024-06

2024

Volltextzugriff (PDF)

Pediatric primary bone lymphoma-diffuse large B-cell lymphoma : Morphologic and immunohistochemical characteristics of 10 cases

American journal of clinical pathology, 2007, Vol.127 (1), p.47-54

2007

Volltextzugriff (PDF)

Adenosine decreases action potential duration by modulation of A- current in rat locus coeruleus neurons

The Journal of neuroscience, 1994-03, Vol.14 (3), p.1114-1122

1994

Volltextzugriff (PDF)

The effects of adenosine on the electrophysiological properties of locus coeruleus neurons

Pan, Wilbur James

1994

Volltextzugriff (PDF)

Bilateral orbital myeloid sarcoma as initial sign of acute myeloid leukemia: case report and review of the literature

Archives of ophthalmology (1960), 2003-01, Vol.121 (1), p.138

2003

Volltextzugriff (PDF)

Two-day collection and pooling of peripheral blood stem cells with semiautomated density gradient cell separation

Journal of hematotherapy & stem cell research, 1999-10, Vol.8 (5), p.561-564

1999

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(33)
Dissertationen
(1)

Sprache

Englisch
(34)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(24)
Humans
(15)
Oncology
(14)
Female
(7)
Male
(7)
Tumors
(7)
Pembrolizumab
(6)
Adult
(5)
Apoptosis
(5)
Biological And Medical Sciences
(5)
Chemotherapy
(5)
Adolescent
(4)
Animals
(4)
Breast Cancer
(4)
Cancer Therapies
(4)
Immunotherapy
(4)
Metastasis
(4)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(3)
Cancer
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: a systematic review and network meta-analysis

Impact of Required Versus Self-Directed Use of Virtual Patient Cases on Clerkship Performance: A Mixed-Methods Study

A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer

A Stroke Mimic: Methotrexate-induced Neurotoxicity in the Emergency Department

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355

Outcomes and patterns of care in a nationwide cohort of pediatric medulloblastoma: Factors affecting proton therapy utilization

Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer

Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1

Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study

Association between event-free survival and overall survival in early-stage triple-negative breast cancer

Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522

PS2-2 KEYNOTE-355 Asian subset: Pembrolizumab + chemotherapy vs placebo + chemotherapy for triple-negative breast cancer

Abstract GS1-02: Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer

Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States

Cost–effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer

Underutilization of proton therapy in the treatment of pediatric central nervous system tumors: an analysis of the National Cancer Database

Abstract PD3-01: Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 study

Neoadjuvant pembrolizumab+chemotherapy/adjuvant pembrolizumab for Early-Stage Triple-Negative breast cancer: Quality-of-Life results from randomized KEYNOTE-522 study

Pediatric primary bone lymphoma-diffuse large B-cell lymphoma : Morphologic and immunohistochemical characteristics of 10 cases

Adenosine decreases action potential duration by modulation of A- current in rat locus coeruleus neurons

The effects of adenosine on the electrophysiological properties of locus coeruleus neurons

Bilateral orbital myeloid sarcoma as initial sign of acute myeloid leukemia: case report and review of the literature

Two-day collection and pooling of peripheral blood stem cells with semiautomated density gradient cell separation

Suchergebnisse filtern